Schedule 13D ownership disclosure
THERAVANCE BIOPHARMA INC
Security class unavailable · CUSIP: G8807B106
Event date: 2016-12-31
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- 9,644,807
- Percent of class
- 18.4000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000903423-17-000038
- Form type
- SC 13D
- Filer
- GSK plc
- CIK
- CIK 1131399
- Filed
- Feb 03, 2017
- Reporting period
- Dec 31, 2016
- Description
- Schedule 13D beneficial ownership